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Abstract
Epithelial-mesenchymal transition (EMT), a mechanism important for embryonic development, plays a critical role during
malignant transformation. While much is known about transcriptional regulation of EMT, alternative splicing of several
genes has also been correlated with EMT progression, but the extent of splicing changes and their contributions to the
morphological conversion accompanying EMT have not been investigated comprehensively. Using an established cell
culture model and RNA–Seq analyses, we determined an alternative splicing signature for EMT. Genes encoding key drivers
of EMT–dependent changes in cell phenotype, such as actin cytoskeleton remodeling, regulation of cell–cell junction
formation, and regulation of cell migration, were enriched among EMT–associated alternatively splicing events. Our analysis
suggested that most EMT–associated alternative splicing events are regulated by one or more members of the RBFOX,
MBNL, CELF, hnRNP, or ESRP classes of splicing factors. The EMT alternative splicing signature was confirmed in human
breast cancer cell lines, which could be classified into basal and luminal subtypes based exclusively on their EMT–associated
splicing pattern. Expression of EMT–associated alternative mRNA transcripts was also observed in primary breast cancer
samples, indicating that EMT–dependent splicing changes occur commonly in human tumors. The functional significance of
EMT–associated alternative splicing was tested by expression of the epithelial-specific splicing factor ESRP1 or by depletion
of RBFOX2 in mesenchymal cells, both of which elicited significant changes in cell morphology and motility towards an
epithelial phenotype, suggesting that splicing regulation alone can drive critical aspects of EMT–associated phenotypic
changes. The molecular description obtained here may aid in the development of new diagnostic and prognostic markers
for analysis of breast cancer progression.
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Introduction
About 90% of human malignancies are carcinomas, tumors of
epithelial origin [1]. The early steps in carcinoma metastasis often
bear a striking resemblance to developmental programs involving
Epithelial-to-Mesenchymal Transition (EMT), a process that
converts organized epithelial cells into isolated, migratory cells
with a mesenchymal morphology [2]. A growing body of work
implicates EMT-like mechanisms in tumor cell invasion and
dissemination in experimental systems and, recently, in human
cancer [3,4]. Normal epithelia are comprised of cells with aligned
apical-basal polarity that are interconnected laterally by several
types of junctions, including adherens junctions (AJs), which play
important roles in establishing and regulating cell-cell adhesion
[5]. During EMT, apico-basolateral polarity is lost, cell-cell
junctions dissolve and the actin cytoskeleton is remodeled to
endow cells with mesenchymal characteristics, including an
elongated, migratory and invasive phenotype. Importantly, as a
consequence of EMT cells may escape tumors, invade the
surrounding tissue and migrate towards blood- or lymphatic
vessels guided by the cells and extracellular matrix present in their
microenvironment [6].
While EMT is thought to promote carcinoma invasion and
metastasis, it is clear that other mechanisms for carcinoma
progression exist [3,7], and direct in vivo evidence linking EMT
to metastasis in clinical subjects has been challenging to obtain.
Some studies have shown that a poor clinical outcome correlates
with markers of EMT progression [8–11]. Conversely, some
reports have identified carcinoma cells in primary and metastatic
lesions with well-differentiated epithelial morphology [7,12].
Detection of EMT in vivo during metastasis is complicated further
by a reverse process, Mesenchymal-to-Epithelial transition (MET),
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that is also important during embryonic development and is
thought to occur during metastatic colonization at secondary sites
[13]. New approaches are needed to detect EMT and MET
during metastatic progression and to clarify their clinical
significance [14,15].
The molecular mechanisms underlying EMT have been studied
extensively in the last decade. EMT-inducing growth factors can
trigger signaling cascades that activate a network of transcription
factors, including Snail, ZEB-1, Goosecoid, FOXC2, Twist and
others [16], that orchestrate the EMT program. Ectopic
expression of a number of the EMT-associated transcription
factors can initiate the program as well. Twist, a potent EMT
driver, was identified originally as an inducer of mesoderm
formation in Drosophila [17]. Ectopic Twist expression in epithelial
cells results in loss of E-cadherin-mediated cell-cell adhesion,
acquisition of mesenchymal markers and increased motility of
isolated cells [18], a hallmark of the mesenchymal phenotype.
EMT is also likely regulated by post-transcriptional mechanisms
including alternative pre-mRNA splicing. Alternative splicing
expands the diversity of the proteome by producing multiple
mRNA and protein isoforms per gene [19]. More than 90% of
human genes are estimated to undergo alternative splicing, with a
majority of alternative splicing events exhibiting tissue-specific
splicing differences [20]. A variety of cancer-associated genes
express alternatively spliced isoforms [21], indicating that
regulation at the level of splicing may play important roles in
cancer onset and progression. Alternative splicing of FGFR2
correlates with EMT in rat bladder carcinoma cells, where
mutually exclusive inclusion of one of two exons defines the ligand
binding specificity of the receptor during EMT [22]. ENAH (also
known as Mena), an actin cytoskeleton regulatory protein,
contains a small coding exon 11a that is included only in epithelial
cells and excluded in mesenchymal cell lines and during EMT
[23,24]. Alternative splicing of p120catenin (CTNND1) generates
protein isoforms that display opposite effects on cell motility in
epithelial and mesenchymal cells [25]. Recently, two epithelial-
specific RNA binding proteins, ESRP1 and ESRP2, homologs of
the nematode splicing factor Sym-2, were identified in a screen for
regulators of FGFR2 splicing [24]. The RBFOX2 splicing factor
has recently been demonstrated to regulate subtype-specific
splicing in a panel of breast cancer cell lines [26]. The ESRPs
and RBFOX2 promote epithelial splicing of a number of
transcripts (including FGFR2 and ENAH), some of which play
important roles in EMT [24,27]. Loss of ESRPs in epithelial cells
induces some EMT-like changes in cell morphology [28].
However, the full extent of alternative splicing during EMT and
its functional consequences to cell phenotype has yet to be
elucidated.
We used an established in vitro model of EMT to evaluate the
amount of gene expression and alternative splicing changes during
EMT. Using deep sequencing analysis of the transcriptomes of
epithelial and mesenchymal cells, we discovered a global alter-
native splicing program that alters splicing of key regulators of cell
phenotype, including proteins that control cell adhesion and
cytoskeletal dynamics. Our analysis indicates that EMT-associated
splicing is likely regulated by several splicing factors, including the
ESRPs and members of the RBFOX, CELF, MBNL, and hnRNP
classes of splicing factors. We found that partial induction of the
epithelial splicing program in mesenchymal cells via ectopic
expression of ESRP1 or by depletion of RBFOX2 conferred
epithelial properties to mesenchymal cells, supporting a key role
for alternative splicing during MET. Multiple EMT-associated
alternative splicing events were identified in breast cancer cell lines
and in primary human breast cancer samples where epithelial and
mesenchymal splicing patterns were negatively correlated. This
EMT-associated splicing signature likely represents a broadly
conserved program involved in the acquisition of mesenchymal-
like phenotypes in vivo that could be used to detect EMT in
primary human cancers with a potentially significant prognostic
value.
Results
Large-scale changes in gene expression accompany EMT
To assess gene and alternative mRNA isoform expression
during EMT, we utilized an in vitro model in which mammary
epithelial cells (HMLE) expressing Twist fused to a modified
estrogen receptor (ER) undergo EMT when the fusion protein is
activated by addition of the ER ligand 4-hydroxytamoxifen (4-
OHT; tamoxifen) [29]. Untreated HMLE/Twist-ER epithelial
cells maintained highly organized cell-cell adhesions and cell
polarity (Figure 1A). Following tamoxifen treatment, the cobble-
stone-like appearance of HMLE/Twist-ER cells was replaced by a
spindle-like, fibroblastic morphology, consistent with previously
published results (Figure 1A; [29]). This morphological transfor-
mation represents one of the hallmarks of EMT. As expected,
phenotypic changes coincided with a change in expression of
canonical EMT markers, including loss of E-cadherin and
induction of N-cadherin, Fibronectin and Vimentin expression
(Figure 1B). Tamoxifen competes with estrogen for binding to ER
to form a complex that translocates into the nucleus where it
recruits co-repressors of transcription, thus preventing activation
of ER downstream targets [30]. Since HMLE cells do not express
endogenous ER (Figure S1B), EMT induction in HMLE/Twist-
ER cells is likely initiated exclusively by downstream targets of
Twist, making HMLE/Twist-ER cells a useful in vitro model of
EMT.
To obtain an in-depth analysis of gene expression and splicing
changes during EMT, we collected mRNA from untreated
(epithelial) and from tamoxifen-treated (mesenchymal) HMLER/
Twist-ER cells. Deep sequencing of fragments of polyA-selected
mRNAs (RNA-Seq) was used to obtain a digital inventory of gene
Author Summary
Epithelial-to-mesenchymal transition (EMT) is the process
by which cancer cells lose their epithelial characteristics
and obtain a mesenchymal phenotype that is thought to
allow them to migrate away from the primary tumor. A
better understanding of how EMT is controlled would be
valuable in predicting the likelihood of metastasis and in
designing targeted therapies to block metastatic progres-
sion. While there have been many studies on the
contribution of changes in gene expression to EMT, much
less is known regarding the role of alternative splicing of
mRNA during EMT. Alternative splicing can produce
different protein isoforms from the same gene that often
have distinct activities and functions. Here, we used a
recently developed method to characterize changes in
alternative splicing during EMT and found that thousands
of multi-exon genes underwent alternative splicing.
Alternative isoform expression was confirmed in human
breast cancer cell lines and in primary human breast
cancer samples, indicating that EMT–dependent splicing
changes occur commonly in human tumors. Since EMT is
considered an early step in metastatic progression, novel
markers of EMT that we identified in human breast cancer
samples might become valuable prognostic and diagnos-
tic tools if confirmed in a larger cohort of patients.
Alternate Splicing in EMT and Cancer
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and mRNA isoform expression (Figure 1A). Between 27 million
and 30 million 39-base-pair (bp) cDNA fragments were sequenced
from each sample (Figure S1A). Sequenced cDNA fragments
(reads) were mapped to the human genome (hg18 version) and to a
splice junction database derived from AceView annotation [31]. In
total, ,75% of reads mapped uniquely to the genome or to splice
junctions, allowing up to 2 mismatches. Less than 1% of total
reads mapped uniquely to rRNA sequences (data not shown).
Read density (coverage) was over 400-fold higher in exons than in
introns or intergenic regions (Figure S1C), indicating that most
reads derived from mature mRNA.
We first estimated gene expression changes during EMT using
‘Reads Per Kilobase of Exon Model per Million Mapped Reads’
(RPKM), a measure of expression that reflects the molar
concentration of a transcript in the sample by normalizing read
counts for mRNA length and for the total read number in the
sample [32]. Applying both a statistical cut-off based on Audic-
Claverie statistics for read-based expression profiling [33] and
requiring a minimum 3- fold change, we observed that ,2,060
genes were downregulated, while ,950 were upregulated in EMT
(Figure S2A), indicating a large-scale reorganization of the
transcriptome during this process in agreement with recently
published data [34]. As expected, E-cadherin was downregulated,
while N-cadherin was upregulated during EMT [18]; actin
transcript levels remained unchanged (Figure S2A). These
observations revealed that Twist-induced EMT is accompanied
by massive changes in gene expression similar to those observed in
developmental EMT [35].
Gene ontology (GO) enrichment analysis of up- and down-
regulated genes was used to gain insight into functional
significance of the EMT-driven expression changes. Genes
involved in epithelial cell differentiation, encoding components
of cell cycle machinery and cell-cell junction components, were
downregulated during EMT (Figure S2B). Concomitantly, genes
associated with cell-matrix adhesion, extracellular matrix organi-
zation and cell motility, were upregulated (Figure S2C). Thus, the
most significant EMT-driven changes in gene expression are
associated with gene categories involved in the phenotypic
conversion that occurs during EMT, in agreement with previously
published data [36].
Alternative isoform expression is grossly affected in EMT
To explore the extent of regulated RNA processing during
EMT, we examined eight common types of alternative isoform
expression events, each capable of producing multiple mRNA
isoforms from a gene through alternative splicing, alternative
cleavage and polyadenylation (APA) and/or alternative promoter
usage (Figure 1D). These eight types of events included: skipped
exons (SE), retained introns (RI), mutually exclusive exons
(MXEs), alternative 59 and 39 splice sites (A5SS and A3SS),
alternative first exons (AFE), alternative last exons (ALE) and
tandem 39 untranslated regions (tandem 39 UTRs). A compre-
hensive set of ,136,000 events of these eight types was derived
from the AceView gene annotations [31]. The fraction of mRNAs
that contained an alternative exon – the ‘percent spliced in’ (PSI or
Y) value – was estimated by the ratio of the density of inclusion
reads to the sum of the densities of inclusion reads and exclusion
reads, with a variant of this method used for tandem 39 UTRs, as
described previously [20]. Thus, Y values range from ,0,
indicating predominant exclusion of an alternative exon from
mRNAs, to ,1, indicating predominant inclusion of the exon.
The extent of EMT-specific regulation of these events was
assessed by comparison of the mesenchymal (post-EMT) to the
epithelial (pre-EMT) RNA-Seq data (Figure 1D). In all, for ,40%
of genes with documented alternative isoforms, both isoforms were
detected by RNA-Seq reads. Of the events where both isoforms
were detected, about 1 in 10 skipped exons and 1 in 20 mutually
exclusive exons exhibited a significant change in Y value .10%,
with hundreds of alternative splicing events of other types also
regulated at this level (Figure 1D). At the gene level, 4.5% of genes
contained an event(s) with an absolute change in Y value greater
than 10% during EMT, and 2% of genes contained an event(s)
with a Y value change greater than 30% (Table S1). These data
indicate that a substantial change in splicing accompanies EMT.
To confirm the accuracy of RNA-Seq analysis of alternative
splicing during EMT, a subset of SE and MXE events was chosen
from the set with False Discovery Rate (FDR) below ,0.05 and
|DY|.0.1 for semi-quantitative RT-PCR (sqRT-PCR) analysis
using cDNA from cells before and after EMT induction.
Alternative splicing events with |DY|.0.1 between human
tissues are enriched for evolutionarily conserved sequences
surrounding the alternative exons as compared to constitutive
exons, suggesting that use of this cutoff enriches for functional
events [20]. The tested subset included 37 alternative exons that
showed relatively large changes in splicing based on the analysis of
the RNA-seq data, or whose host genes encoded functionally
interesting molecules with respect to EMT (e.g., adhesion
molecules). This subset also included a few events that showed
relatively small changes in isoform expression in order to assess the
robustness of our statistical test. In all cases, the change in splicing
DY ( =YM2YE) detected by RT-PCR was in the same direction
as that determined by RNA-Seq (Figure S1D), and in 78% of
cases, the change in Y observed by sqRT-PCR was 20% or
higher. Altogether, a strong concordance (R2 = 0.86; Figure S1D)
was observed between splicing changes detected by RNA-Seq and
measurements by sqRT-PCR. The high validation rate and
quantitative concordance by an independent method (sqRT-PCR)
support the reliability of the alternative splicing events identified
by the RNA-seq analysis.
Genes with altered splicing during EMT showed strong
enrichment for involvement in biological processes related to the
regulation of the actin cytoskeleton, cell-cell junctions, regulation
Figure 1. Alternative mRNA isoform expression in EMT. (A) Schematics of the in vitro EMT induction experiment. Immortalized human
mammary epithelial cells (HMLE) expressing Twist fused to Estrogen Receptor (ER) were induced to undergo EMT by addition of tamoxifen into the
culture media. mRNA was collected before EMT induction (epithelial sample) and after EMT induction (mesenchymal sample). cDNA pools from both
samples were deep sequenced (RNA-Seq) and analyzed (See Materials and Methods). (B) Western blot analysis of N-cadherin, E-cadherin, fibronectin
and vimentin expression with antibodies as indicated in cell lysates that were obtained before (1- untreated) and after (2- tamoxifen-treated)
induction of EMT in HMLE/Twist-ER cells. a- tubulin was used as a loading control. (C) Gene ontology enrichment analysis bar graph of changes in
alternative splicing events with |DY|.=10% between samples. Gene ontology ‘biological process’, GO_BP_FAT, annotation is indicated in red on the
y axis. KEGG Pathway (http://www.genome.jp/kegg/) annotation is indicated in blue on y axis. Benjamini FDR (2log10) is indicated on the x axis.
Vertical dotted line marks Benjamini FDR= 0.05. (D) Column 1 shows different kinds of splicing events that have been analyzed. Columns 2–5 show
the number of events of each type: (2) all known events based on AceviewAceView annotation; (3) events with both isoforms supported by RNA-Seq
reads; (4) events detected at a False Discovery Rate (FDR) of 5% with DY .= 10% between samples; (5) events detected at an FDR of 5% with
DY.= 30% between samples.
doi:10.1371/journal.pgen.1002218.g001
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of cell migration and wound healing. Pathway analysis using
KEGG and GO detected enrichment of EMT-associated
alternative splicing events in the Wnt, Ras and Insulin pathways
(Figure 1C). These enriched terms suggested that alternative
splicing plays a role in pathways that direct morphological and
motility-related changes associated with EMT. Interestingly,
although the types of gene functions most affected at the splicing
and expression levels were largely similar, the actual sets of genes
undergoing splicing-level and expression-level changes did not
overlap more than expected by chance (Figure S3). This
observation suggests that the EMT splicing program functions in
a manner that is parallel to the transcriptional program and that
gene expression and alternative splicing, may coordinately drive
changes to specific aspects of cell morphology related to the
cytoskeleton, cell adhesion and cell motility.
Regulatory motifs and factors associated with the EMT
splicing program
A substantial shift in the levels or activity of the major splicing
factors likely underlies the large-scale program of splicing changes
that occur during EMT. To explore the nature of this shift, we first
analyzed the incidence of oligonucleotide motifs occurring in
regulated alternative transcripts. As most splicing factors bind
short RNA oligomers a few bases long, we identified pentanucleo-
tides (5mers) that were enriched in regions adjacent to the splice
sites involved in the splicing of exons induced or repressed upon
EMT (Figure 2A). This analysis identified a few dozen 5mers
enriched in each region relative to control alternative introns,
including motifs corresponding to the RBFOX, CELF, ESRP and
MBNL families of tissue-specific factors, as well as motifs for
several heterogeneous nuclear ribonucleoprotein (hnRNP) factors,
including hnRNPs F and H, PTB/hnRNP I, and hnRNP L (Table
S2, S3). A subset of these motifs was specifically enriched adjacent
to exons whose Y values increased following EMT relative to
exons whose splicing did not change (Figure 2A). These included
motifs associated with RBFOX and ESRP splicing factors and
with hnRNPs F/H and L. An overlapping subset of motifs were
enriched adjacent to exons whose Y values decreased following
EMT, again including motifs associated with the RBFOX and
hnRNP F/H families and also motifs associated with PTB and
MBNL family proteins (Figure 2A). Several 5-mers, without clear
RNA binding protein partners, that may represent binding sites of
uncharacterized splicing regulators in EMT were also identified.
We also examined changes in the expression of RNA binding
protein (RBP) genes. The most striking changes in RBP expression
occurred for the related epithelial specific splicing factors ESRP1
(RBM35A) and ESRP2 (RBM35B) [24]. During EMT, the
expression of these factors decreased by ,90-fold and ,35-fold,
respectively, from relatively high initial levels (Figure 2B). Motif
enrichment for ESRP splicing factors was observed in the
upstream sequence of cassette exons upregulated during EMT
(Figure 2A) consistent with the recent observation that ESRP
binding sites are present at greater numbers upstream of silenced
exons, than included exons [28]. As ESRPs are downregulated
during EMT, these silenced exons are relieved from ESRP
inhibition and thus appear upregulated.
Splicing factor activity often switches between positive and
negative regulation depending on the location of binding relative
to the regulated exon. RBFOX family splicing factors tend to
enhance splicing when bound downstream and to repress splicing
when bound upstream of alternative exons [27]. The observed
pattern of enrichment of RBFOX motifs downstream of exons
whose inclusion increased during EMT and upstream of exons
whose inclusion decreased (Figure 2A) is therefore consistent with
an increase in the activity of RBFOX family factors during EMT.
Expression of the RBFOX2 gene increased moderately but
significantly by about 15% following EMT (Table S4) while at
the same time splicing of a MXE encoding the RNA-binding
domain of the RBFOX2 protein increased by about 20%. Thus,
these changes together should increase the levels of splicing-active
RBFOX2 mRNA by at least a third. Recently, it has been
suggested that RBFOX2 activity plays a role in regulating a set of
breast cancer subtype–specific alternative splicing events [26]. The
expression levels of many other RBPs associated with motifs
enriched near EMT-regulated exons changed during EMT
(Figure 2B, Table S4), including downregulation of the splicing
repressor PTBP1 (PTB/hnRNP I) by ,2.5-fold, downregulation
of the PTB-associated splicing co-repressor RAVER1 by ,4-fold,
and downregulation of the myotonic dystrophy-associated splicing
factors MBNL2 and MBNL3 and hnRNP F by ,1.6- to 2.5-fold.
These observations suggested that changes in the levels and
activity of several different splicing factors may contribute to the
splicing changes observed in EMT.
To explore the potential contributions of splicing factors to
EMT-regulated alternative splicing, we analyzed published cross-
linking/immunoprecipitation-sequencing (CLIP-Seq) data from
human cell lines. Dozens of EMT-regulated skipped exons were
associated with RBFOX2 CLIP-Seq clusters, and hundreds were
associated with PTB CLIP-Seq clusters (Figure 2C; [27,37]). In
addition, a fraction of the observed EMT-regulated splicing events
overlapped with a set of ESRP1-regulated exons recently identified
by Carstens and coworkers using RNAi and a splicing-sensitive
microarray analysis (Figure 3C; [28]). Together, the RNAi and
CLIP-Seq data demonstrate the potential for regulation of a
substantial portion – perhaps a majority of EMT-regulated exons
– by these three factors. Thus, our data are consistent with a model
in which several splicing factors collaborate in the regulation of
splicing during EMT, adding a layer of post-transcriptional
regulation to the EMT program.
EMT–associated alternative transcripts correlate with the
phenotype of breast cancer cell lines
Alternatively spliced mRNA isoforms that exhibit EMT-
associated changes in exon inclusion might serve as valuable
prognostic markers for metastatic disease, since EMT is considered
an early event in metastatic progression. As an initial step towards
eventual analysis of primary human samples, we assessed
alternative isoform expression in a panel of human breast cancer
cell lines of luminal (generally poorly metastatic) and basal-like
origin (generally aggressive and metastatic). Luminal cell lines, like
MCF7 and T47D, express high levels of epithelial markers
including E-cadherin, while basal-like cell lines express mesen-
chymal markers including N-cadherin, vimentin and fibronectin
[14]. In addition, in our analysis we included two cell lines –
derivatives of MDA-MB-231 cell metastases to the brain and bone
– that exhibited a more aggressive phenotype compared to the
parental MDA-MB-231 cells [38]. We hypothesized that splicing
events with high epithelial inclusion (i.e. high inclusion in the pre-
EMT/epithelial sample) would be expressed in luminal breast
cancer cell lines, and conversely that splicing events with high
mesenchymal inclusion (defined analogously) would be expressed
in basal-like cell lines. A quantitative RT-PCR (qRT-PCR)
analysis of nine skipped exons demonstrating the largest DY in
the validated set of 37 alternative splicing events, using cDNA
from the panel of luminal and basal-like cell lines, indicated that
four epithelial inclusion events, in the SLC37A2, KIF13A, FLNB,
and MBNL1 genes, were included at high frequency in luminal
cell lines, whereas inclusion of these events was low in basal-like
Alternate Splicing in EMT and Cancer
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cells compared to T47D epithelial cells (Figure 3A). Conversely,
five mesenchymal-enriched inclusion events in the PLEKHA1,
MLPH, ARHGEF11, CLSTN1 and PLOD2 genes were enriched
in basal-like cell lines with only low inclusion levels in luminal cells
relative to BT549 mesenchymal cells (Figure 3B), consistent with
recently published results [28]. Thus, taken together, epithelial
inclusion events were identified in corresponding mRNA tran-
scripts in luminal cells and were detected at very low levels in
Figure 2. Motif analysis reveals splicing factors that are involved in the regulation of EMT–specific splicing. (A) Pentamer motifs
significantly enriched (FDR,0.1) in the 4 flanking 250-nt intronic regions of EMT-regulated skipped exons. Statistics of motifs resembling known
binding sites of splicing factors are annotated as described in the key. Motifs that are not recognized as known binding sites are grouped into the
‘‘Other’’ group. * = at least one known motif of that splicing factor has an FDR,0.05. (B) Scatter plot of expression levels of RNA binding proteins and
mRNA splicing regulators in epithelial and mesenchymal cells. Some splicing factors whose motifs were enriched in (A) are highlighted. Asterisks
mark splicing factors which are also regulated by alternative splicing of their mRNA transcripts. Genes encoding components of cleavage/
polyadenylation machinery are also highlighted. (C) A venn diagram showing potential regulation of EMT-associated skipped exon events by ESRP1,
PTP and RBFOX2 splicing factors based on the microarray analysis of ESRP1 depleted MDA-MB-231 cells [28] and CLIP-Seq analysis of FOX and PTB
[27,37] (See Text S1). The universe of the Venn diagram consists of all EMT-regulated SE events by FDR of 5% and |DY|.= 10%. P (FOX2) = 8.58e-05;
p (PTB) = 0.0013; p (ESRP1) = 9.27e-16.
doi:10.1371/journal.pgen.1002218.g002
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basal-like cells, while mesenchymal inclusion events were detected
at low levels in luminal cells but showed a high inclusion ratio in
basal-like cells (Figure 3C, 3D). Therefore, the qRT-PCR analysis
of skipped exons using cDNA from a panel of luminal and basal-
like breast cancer cell lines detected EMT-associated splicing
events, as predicted by the RNA-seq analysis of Twist-induced
EMT.
To explore the expression of EMT-associated alternative
splicing events in breast cancer cell lines further and to determine
whether EMT-associated alternative exons could classify breast
cancer cell line subtypes, we compared the expression of skipped
exons (SEs) from our EMT RNA-seq analysis to available exon
array data from luminal and basal B breast cancer cell lines in the
NCI-60 panel [39]. Unsupervised hierarchical clustering of exon
array data relating to 307 EMT-associated SE events (|DY|.0.1,
FDR,0.05; foreground set) detected by the array, segregated
basal B cell lines from luminal cell lines with only two basal cell
lines (MDA-MB-436 and SUM149) misclassified in the luminal
cluster (Figure 4A). In contrast, clustering of the exon array data
using the background set of 8839 events resulted in cell line
subtype classification with nine misclassifications, indicating lack of
intrinsic bias in the whole set of analyzed events and that the SE
events identified by our EMT RNA-Seq better classify the luminal
and basal B cell lines. Furthermore, a randomized-clustering
procedure demonstrated that the clustering classification using our
set of SE events was statistically significant (p-value = 0.0014).
Therefore, the EMT-associated splicing program identified by our
RNA-seq analysis is conserved in breast cancer cell lines and
correlates with their invasive and metastatic properties.
We hypothesized that some of the heterogeneity in splicing
observed across the cell lines stemmed from cell type specific
splicing events that may not be linked directly to EMT regulation
(Figure 4A). To find the ‘‘core’’ EMT alternative splicing signature
that can unambiguously distinguish between breast cancer cell line
subtypes, we compared EMT-driven SE events to the SE events
that were differentially regulated between the luminal and basal B
Figure 3. EMT–associated alternative splicing events are confirmed in breast cancer cell lines. (A) Alternative exon inclusion in four
mRNA transcripts, as indicated, in eight breast cancer cell lines determined by a qRT-PCR analysis and depicted as a fold change relative to exon
inclusion in T47D luminal cell line. (B) Alternative exon inclusion in five mRNA transcripts, as indicated, in eight breast cancer cell lines depicted as a
fold change relative to exon inclusion in BT549 basal B cell line. (C) Distribution of all epithelial inclusion events combined. Each event is depicted as a
fold change relative to inclusion in T47D. (D) Distribution of all mesenchymal inclusion events combined. Each event is depicted as a fold change
relative to inclusion in BT549 cells. For (C) and (D), *** = p,0.001.
doi:10.1371/journal.pgen.1002218.g003
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cell lines. Of the SE events represented on the array that changed
significantly in our EMT RNA-Seq dataset (|DY|.0.1,
FDR,0.05), a total of 24 events changed significantly between
luminal and basal B cell lines at an FDR,0.25. Of these, 19 (79%)
changed in a ‘‘coherent’’ manner in the sense that the change in
exon inclusion was in the same direction between mesenchymal
and epithelial samples in the EMT RNA-seq dataset as between
basal B and luminal cell lines in the exon array dataset (Figure S4).
Interestingly, coherence increased for events that changed more
dramatically in the EMT RNA-Seq dataset, with 11 (100%) of SE
events (RNA-seq |DY|.0.3) exhibiting coherence between the
two datasets (Figure S4). Notably, clustering analysis of luminal
and basal B breast cancer cell lines using 19 coherent SE events
demonstrated that luminal cell lines could be unambiguously
distinguished from basal B cell lines based exclusively on these
splicing events alone (Figure 4B). These ‘‘core’’ EMT-associated
alternative splicing events may comprise a common program that
contributes to the phenotypic changes that endow cancer cells with
invasive and metastatic capabilities.
Alternative isoforms detected in the in vitro EMT model
are expressed in primary human breast cancer samples
To determine whether the alternative mRNA isoforms
confirmed in human breast cancer cell lines are relevant to
human disease, we assessed expression of these events in fine
needle aspiration (FNA) biopsies from breast cancer patients. FNA
is the least invasive available method of collecting diagnostic
material from patients with breast mass. This procedure is
performed using a small gauge needle that gently disrupts the
tissue and allows loose tumor cells to travel up the needle via
capillary action. The FNA sample is usually enriched in tumor
cells and can be analyzed by qRT-PCR [40]. However, due to the
small volume of the sample, RNA recovery is low – tens of
nanograms of total RNA at most. As expected, a subset of patient
FNA spreads contained tumor cells that appeared cohesive and
tightly attached to each other, typical of benign ductal lesions,
while another subset of FNA smears from invasive ductal
carcinomas (IDCs) contained discohesive populations of enlarged
tumor cells (Figure 5A), typical for a highly invasive phenotype.
Analysis of 15 random FNA smears from IDCs used in this study
for the percentage of tumor, inflammatory and stromal cells
demonstrated an almost a complete absence of adipocytes,
macrophages and inflammatory cells (Figure S5), indicating that
all of the cells present in FNA samples were ductal cancer cells.
Therefore, the phenotypic characteristics of FNA collected
samples indicated that they represent an appropriate human
sample for assessment of alternative mRNA transcript expression
found in our in vitro screen for EMT-associated splicing.
To check expression of alternative mRNA isoforms, we
obtained FNA samples from 40 patients with IDCs of various
grades and growth hormone receptor status. IDCs in patients were
classified as well, moderately or poorly differentiated according to
the modified Bloom Richardson scale. The clinical and demo-
graphic data including patients’ age, tumor size, lymph node
status, estrogen, progesterone and Her2/neu receptor status were
also collected (Table S5). Using the cDNA from 40 IDC samples,
we determined inclusion ratios for six SE events that exhibited the
largest change in exon inclusion levels based on the analysis of
breast cancer cell lines. These included epithelial inclusion events
in ENAH, MBNL1, FLNB and SLC37A2, and mesenchymal
inclusion events in MLPH and ARHGEF11 (Figure 5B). The
small amount of RNA isolated from FNA samples permitted
analysis of only six alternative splicing events per sample. Inclusion
ratios of splicing events in IDC samples were normalized to the
average inclusion ratio of the same splicing event measured in six
fibroadenoma (FA) samples. For each pair of splicing events, the
Pearson correlation between normalized inclusion ratios of the two
splicing events across 40 IDC samples was calculated and used for
clustering analysis to assess the relationships between events
(Figure 5C). Interestingly, ENAH and SLC37A2 as well as MLPH
and ARHGEF11 inclusion events were highly correlated. Some
epithelial and mesenchymal inclusion events were inversely
correlated, e.g., increases in FLNB inclusion tended to be
associated with decreases in inclusion of the ARHGEF11
alternative exon. Little or no correlation was observed between
SLC37A2 and MLPH inclusion events. Overall, many IDCs
expressed the mesenchymal mRNA isoforms, indicating that
EMT-associated splicing occurs in human tumors in vivo.
Unsupervised clustering of splicing ratios of six alternative exons
in 34 FNA samples demonstrated a significant correlation between
the two mesenchymal markers, MLPH and ARHGEF11, and
between the four epithelial markers, ENAH, SLC37A2, FLNB
and MBNL1, while epithelial and mesenchymal marker groups
exhibited anti-correlation (Figure S6A). Approximately Unbiased
(AU) p-values obtained from the Pvclust analysis (http://www.is.
titech.ac.jp/,shimo/prog/pvclust/) were .99%, thus supporting
reliability of the clustering tree (Figure S6B). This result suggests
that the IDC samples tended to have either epithelial or
mesenchymal splicing patterns but rarely exhibited mixed
inclusion patterns, indicating that IDCs could be unambiguously
classified into two groups on this basis.
The ESRP1 splicing factor confers epithelial-like
properties to mesenchymal cells
By far the most strongly downregulated RBPs in EMT were the
related factors ESRP1 and ESRP2 (Figure 2B; Table S4). These
factors have been proposed to promote an epithelial phenotype by
facilitating epithelial-specific splicing of a number of genes, some
of which have well documented and essential roles in EMT
[24,41]. Silencing of ESRP1/2 in epithelial cells induced N-
cadherin expression without affecting E-cadherin levels and led to
a slight, but significant, increase in the rate of monolayer wound
healing [28]. We hypothesized that expression of ESRP1 in
mesenchymal cells would convert a portion of the mesenchymal
splicing program to an epithelial state and allow us to examine the
role of alternative splicing in the context of Mesenchymal-to-
Epithelial Transition (MET). We introduced ESRP1-EGFP into
HMLE/pBP-Twist cells, immortalized human mammary epithe-
lial cells that ectopically express Twist [18], and analyzed
expression of canonical EMT markers. As expected, control
HMLE/pBP epithelial cells expressed high levels of E-cadherin
while HMLE/pBP-Twist mesenchymal cells expressed high levels
of N-cadherin (Figure 6A; [18]). Expression of ESRP1 in HMLE/
pBP-Twist cells was sufficient to switch ENAH splicing to an
Figure 4. EMT–associated alternative mRNA isoforms classify breast cancer subtypes. (A) Unsupervised hierarchical clustering of NCI-60
breast cancer cell lines [39], as indicated, using the 307 EMT-associated SE events (|DY|.0.1, FDR,0.05). Luminal cell lines are marked in blue. Basal B
cell lines are marked in red. Shades of yellow indicate positive pearson correlation. Shades of blue indicate negative pearson correlation. The color
scale is shown on the right. The dotted line separates luminal and basal cell line clusters. (B) Clustering correlation matrix of NCI-60 breast cancer cell
lines [39], as indicated, using the 24 coherent events.
doi:10.1371/journal.pgen.1002218.g004
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epithelial pattern, as evident by the inclusion of epithelial-specific
11a exon of ENAH (Figure 6A). However, ESRP1-expressing cells
still had high levels of N-cadherin and low levels of E-cadherin.
Thus, ESRP1 expression is sufficient to alter splicing of some
targets but is not sufficient to alter expression of EMT markers in
mesenchymal cells.
One important consequence of EMT is altered cell migration. To
assess the effect of ESRP1 expression on cell migration qualitatively,
we analyzed cell the movement of cells migrating out of a matrigel
drop by time-lapse microscopy. This assay is similar to a standard ex
vivo EMT assay used in the studies of developmental EMT to assess
cell migration of endocardial cushion explants [42]. Cells were
reconstituted in a small volume of matrigel and allowed to migrate
out of the cell-matrigel drop for 24 hrs (Figure S7). Almost no
difference in migration was observed in 8 hrs between control
epithelial cells, mesenchymal cells and the same cells expressing
ESRP1. However, by 19 hrs the epithelial HMLE/pBP cells
continued to migrate as an epithelial sheet, keeping in tight contact
with each other, while HMLE/pBP- Twist mesenchymal cells
acquired a spindle-shaped morphology, migrated as individual cells
and for a longer distance than epithelial cells during the same time
period (Figure S7). Interestingly, HMLE/pBP-Twist cells expressing
ESRP1 became elongated but continued to move in contact with
each other. These differences in migration were further manifested
at 24 hrs, suggesting that ESRP1 expression conferred epithelial-
like properties to the migration of mesenchymal HMLE/pBP-Twist
Figure 5. Alternative mRNA isoforms are expressed in FNA samples from breast cancer patients. (A) An example of a fine needle
aspiration (FNA) spread from a benign and an invasive human breast tumor. (B) A table describing gene names, gene functions, change in inclusion
levels during EMT (DY) and proposed functions of six SE events used in the FNA qRT-PCR analysis in (C). (C) Heat plot of pairwise Pearson correlation
coefficients obtained from correlation analysis of exon inclusion ratios in 40 IDC samples normalized to an average fibroadenoma sample exon
inclusion for six alternative splicing events. Yellow indicates a correlation of 1, black indicates a correlation of 0, light blue indicates a correlation of
21. Shades of yellow and blue mark correlation in-between.
doi:10.1371/journal.pgen.1002218.g005
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cells (Figure S7). To analyze the migration characteristics of
mesenchymal cells upon ESRP1 expression quantitatively, we
utilized an ‘‘in monolayer’’ migration assay [43] that evaluates the
movement of individual cells within a monolayer in contrast to a
‘‘sheet monolayer’’ motility assay which assesses collective cell
migration towards an open wound [44]. Epithelial HMLE/pBP
Figure 6. Expression of ESRP1 confers epithelial migration properties to mesenchymal cells. (A) Western blot analysis of cell lysates from
HMLE/pBP, HMLE/pBP-Twist and HMLE/pBP-Twist/ESRP1 cells probed with antibodies as indicated. a- tubulin was used as a loading control. (B) Still
images from a live cell-tracking experiment of cells, as indicated, labeled with a cellular dye CMFDA and plated in the monolayer mixed 1:20 with
unlabelled cells. Cells were tracked for 12 hours. Cell tracks were generated using semi-automated cell tracking and represent single cell tracks over
12 hours with 10 minutes intervals. Centroids of fluorescent cells are indicated by grey circles. Videos are provided as Videos S1, S2, S3. Windrose
plots of the range of motion of individual cells of each cell type are shown next to still images from a live-cell imaging experiment, as indicated.
Windrose plots were generated by placing starting points of all cell tracks obtained in the cell tracking experiment into the same spot. (C) The box
plot depicts speed distribution of individual cells inferred from live-cell imaging of cells in (A) and analyzed by the Imaris software. Edges of the boxes
indicate 25th and 75th percentile and the whiskers 5th and 95th percentile. The line in the box indicates the median of the distribution. n = 138 cells for
HMLE/pBP; n = 125 cells for HMLE/pBP-Twist; n = 113 cells for HMLE/pBP-Twist/ESRP1-EGFP. *** = p,0.001.
doi:10.1371/journal.pgen.1002218.g006
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cells migrate efficiently only when plated in a monolayer in contact
with other cells, while mesenchymal HMLE/pBP-Twist cell
movement is attenuated by cell-cell contact (H.D. Kim, FBG and
D.Lauffenburger, unpublished observations). Control HMLE/pBP
epithelial cells, HMLE/pBP-Twist mesenchymal cells and HMLE/
pBP-Twist cells expressing ESRP1-EGFP were labeled with whole-
cell tracking dye and plated along with the equivalent unlabeled cell
types such that the labeled cells represented 5% of cells within a
confluent monolayer to assess migration in the presence of cell-cell
contact (Figure S8A). As expected, epithelial cells exhibited
significant movement in a 17 hr cell tracking experiment [43,45],
while confluent mesenchymal cells moved a little, if at all (Figure 6B;
Videos S1, S2). Surprisingly, upon expression of ESRP1, mesen-
chymal cells demonstrated significant locomotion, bypassing their
typical contact inhibition of motility and instead resembling the
movement of epithelial cells in a monolayer (Figure 6B; Video S3).
Windrose plots of cell movement, where all cell tracks are placed at
the same starting point, clearly demonstrated the extent of motion
for each cell type (Figure 6B). While many epithelial HMLE/pBP
cells traversed paths of up to 300 mm in length, mesenchymal
HMLE/pBP-Twist cells moved less than 100 mm. Interestingly,
many ESRP1 expressing mesenchymal cells exhibited intermediate
range of motion of about 200 mm (Figure 6B). Analysis of the cell
movement parameters revealed that the speed of ESRP1-
expressing cells was significantly increased compared to the speed
demonstrated by mesenchymal cells without ectopic ESRP1
expression (Figure 6C). The total path and overall displacement
of HMLE/pBP-Twist/ESRP1 cells were also increased significantly
(Figure S8B). The most likely explanation of this data is that splicing
changes resulting from ESRP1 expression are sufficient to shift the
migration properties of mesenchymal cells towards an epithelial-like
phenotype. However, we cannot rule out indirect effects or possible
uncharacterized functions of ESRP1.
The actin organization and structure of cell-cell contacts have a
substantial effect on the migration of cells within monolayers. To
characterize phenotypic changes underlying differences in cell
migration behavior of epithelial HMLE/pBP cells, mesenchymal
HMLE/pBP-Twist cells, and HMLE/pBP-Twist cells expressing
ESRP1, immunofluorescence analysis was used to visualize actin
organization and cell-cell junctions (Figure 7A; Figure S9). As
expected, three-dimensional structured illumination microscopy
revealed the presence of circumferential actin belt in epithelial cells,
while actin stress fibers prevailed in mesenchymal cells (Figure 7B).
Interestingly, actin organization was altered in mesenchymal cells
upon expression of ESRP1. While some stress fibers were present in
the central part of the cell, prominent accumulation of peripheral
circumferential actin, characteristic of epithelial cell morphology,
was also observed. p120catenin, a marker for cell-cell adhesions,
decorated areas of cell-cell contact in HMLE/pBP cells, while in
HMLE/pBP-Twist cells p120catenin localization was barely visible
at cell contact points and could be observed only in areas where
adjacent cells overlapped without forming obvious junctions
(Figure 7B). Expression of ESRP1 led to increased recruitment of
p120catenin to the sites of cell-cell adhesion (Figure 7B). The tight
junction marker ZO-1 as well as alpha-catenin localized to actin
filaments that perpendicularly terminated at cell-cell borders in
immature cell-cell junctions of epithelial cells. In contrast, ZO-1 and
alpha-catenin localized to the sites of focal cell-cell contact at the
ends of stress fibers in mesenchymal cells (Figure 7A; Figure S9A).
Interestingly, expression of ESRP1 in mesenchymal cells led to
patterns of ZO-1 and alpha-catenin resembling their localization in
epithelial cells. Thus, ESRP1 expression in mesenchymal cells
partially reverted actin organization and cell-cell junction morphol-
ogy towards the epithelial phenotype.
A defining feature of epithelia and endothelia is to separate
compositionally distinct fluid phase compartments by providing a
barrier to ion and solute passage, a prerequisite for the
development of most organ systems in vertebrates [46,47]. To
assess whether the change in actin organization and cell-cell
junction morphology in mesenchymal cells upon expression of
ESRP1 would have functional consequences, we compared the
ability of fluorescently tagged dextran to cross a confluent
monolayer of epithelial HMLE/pBP cells, mesenchymal
HMLE/pBP-Twist cells and the same cells expressing ESRP1.
As expected, permeability of the HMLE/pBP-Twist cell mono-
layer was almost two-fold higher than permeability of the HMLE/
pBP cell monolayer (Figure 7C). Strikingly, expression of ESRP1
in HMLE/pBP-Twist cells increased their barrier function
significantly, resulting in permeability that was less then 1.5 fold
higher than control epithelial cells (Figure 7C). Thus, expression of
ESRP1 lead to a substantial increase in barrier function of
mesenchymal cells, caused by the epithelial-specific splicing
induced in mesenchymal HMLE/pBP-Twist cells. These results
suggest that ESRP1-mediated splicing changes may drive
epithelial-like re-organization of peripheral actin and cell-cell
junctions that underlie barrier function.
Depletion of RBFOX2 in mesenchymal cells leads to a
partial reversion towards epithelial phenotype
As noted above, our analysis along with published data [26]
suggest that the RBFOX2 splicing factor likely controls a
substantial subset of EMT-dependent alternative splicing
(Figure 2A, 2C). To assess the effect of RBFOX2 depletion on
cell phenotype, we treated HMLE/pBP-Twist mesenchymal cells
with scrambled shRNA or with shRNA targeting RBFOX2. qRT-
PCR analysis demonstrated ,80% depletion of RBFOX2 mRNA
(Figure S10A), while RBFOX2 protein levels became virtually
undetectable (Figure S10C). RT-PCR analysis of the known
RBFOX2 targets FAT and PLOD2 [26] confirmed changes
consistent with depletion of RBFOX2 activity. In mesenchymal
cells treated with RBFOX2 shRNA, FAT alternative exon
inclusion was reduced from 40% to 5%. A less dramatic but
significant effect on exon inclusion was also observed for the
PLOD2 alternative exon (Figure S10B).
Expression of many EMT markers was unaffected by RBFOX2
depletion. No difference in expression was observed for N-
cadherin and fibronectin compared to scrambled shRNA-treated
control cells (Figure S10C). However, vimentin levels were
reduced, indicating a partial loss of the mesenchymal expression
program in HMLE/pBP-Twist cells upon RBFOX2 knockdown.
Immunofluorescence analysis revealed that RBFOX2 depletion in
mesenchymal HMLE/pBP-Twist cells shifted their morphology
from spindle-shaped to cobblestone-like, resembling epithelial cell
morphology (Figure S10D). Stress fibers, prominent in HMLE/
pBP-Twist cells, were not readily observed after RBFOX2
depletion. Junctional markers like ZO-1, p120catenin and alpha-
catenin brightly decorated cell-cell contacts, suggesting that cell
junctions were formed in these cells in contrast to HMLE/pBP-
Twist mesenchymal cells, where these markers were barely visible
at sites of cell-cell contact (Figure S10D). Qualitative assessment of
cell migration properties using a matrigel drop assay described
above demonstrated that HMLE/pBP-Twist cells expressing a
scrambled shRNA exhibited an individual cell migration pattern
and scattered in 24 hrs of plating characteristic of mesenchymal
cells. In contrast, cells expressing RBFOX2 shRNA migrated as a
sheet, staying in contact with each other (Figure S10E). Together,
these data suggests that, similar to ectopic ESRP1 expression,
knockdown of RBFOX2 conferred a number of epithelial features
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to mesenchymal cells, presumably by shifting their splicing
program from mesenchymal to partially epithelial.
Discussion
In the present study, we profiled the transcriptome of human
mammary epithelial cells induced to undergo EMT by activation
of Twist, a transcription factor important for EMT induction
during embryonic development and metastasis. Using this system,
we observed an EMT-associated global change in alternative
splicing of a number of genes that are involved in functions crucial
for EMT progression, such as cell adhesion, cell motility, and
cytoskeletal remodeling. Several of the splicing changes discovered
in vitro were also found to occur in a panel of breast cancer cell
lines and in vivo in primary human breast cancer samples. We also
demonstrated that expression of an epithelial specific splicing
factor, ESRP1, was sufficient to cause a substantial shift in the
actin organization, migration properties and barrier function of
mesenchymal cells towards the epithelial phenotype, while
depletion of the splicing factor RBFOX2 also conferred some
epithelial properties to mesenchymal cells. Altogether, the present
evidence leads us to propose that alternative splicing plays a major
role in EMT and tumor progression by changing alternative
isoform expression of genes important for epithelial and
mesenchymal cell morphology and motility.
Changes in alternative splicing contribute to
pathological EMT
Transcriptional regulation of EMT has been a focus of
numerous studies in cancer cell lines and primary tumor samples
in the last decade [15]. A number of transcription factors have
been identified that repress key regulators of EMT such as E-
cadherin, and induce transcription of the drivers of mesenchymal
phenotype, including N-cadherin and vimentin [16,18,48,49].
Changes in alternative isoform expression during EMT have been
observed previously only for a handful of genes including FGFR2,
p120catenin, ENAH and CD44 [22–25,50]. Recently, epithelial-
specific splicing factors ESRP1 and ESRP2 have been shown to
regulate splicing of a subset of genes that contribute to the
epithelial phenotype [28]. However, the extent to which
coordinated changes in splicing might contribute to phenotypic
and morphological changes during EMT has not been investigated
systematically. Our results demonstrate that thousands of genes
undergo changes in alternative isoform expression during EMT,
establishing the existence of a program of alternative RNA
processing accompanying EMT.
Many of the alternative splicing events we observed may have a
major effect on protein functions important for EMT, including
regulation of cell migration, cell adhesion and actin cytoskeleton
remodeling (See Figure 5B; Table 1). For example, inclusion of
alternative exon in the C-terminus of ARHGEF11, a Rho guanine
nucleotide exchange factor (GEF) 11, also known as PDZ-
RhoGEF, is increased in mesenchymal cells. Interestingly, removal
of the C-terminus of ARHGEF11 results in a remarkable increase
in its ability to induce RhoA activation in vivo and promotes
neoplastic transformation [51]. Furthermore, components of key
pathways that control cell motility, invasion and EMT itself are
affected by alternative splicing (Table 1), including components of
the Wnt and TGF-b signaling pathways. Some RNA regulatory
proteins were also affected. For example, increased inclusion of
exon 5 of the splicing factor MBNL1 was detected in epithelial
cells, a change that occurs in models of myotonic dystrophy and
alters the intracellular localization of the protein from cytoplasmic
to nuclear [52–54]. Interestingly, several previously uncharacter-
ized mRNA isoforms of genes that control important aspects of
EMT have been found in this analysis. For example, a 40%
increase in inclusion of a 26 aa region in SCRIB (a homolog of
Drosophila scribble), involved in regulation of apical-basal polarity
and directional migration of epithelial cells [55,56], was observed
in mesenchymal cells that might alter a PKC phosphorylation site.
This suggests that a cDNA containing this 26 aa exon may not
encode the appropriate isoform to use when studying the function
of SCRIB in epithelial cells. Altogether, our analysis demonstrates
that alternative splicing in EMT leads to changes in protein
functions in ways that contribute to the establishment of
mesenchymal phenotype, and identifies many widely studied
molecules with the potential for significant isoform-dependent
functions during EMT.
Could key aspects of EMT and/or MET be driven by splicing
changes alone, independent of the transcriptional machinery?
Recent data suggests that systemic dissemination of tumor cells
occurs at early stages of tumor development [57], therefore,
targeting MET therapeutically might prove more effective since at
the time of diagnosis it may already be too late to successfully
target EMT-inducing events. Thus we chose to assess contribution
of changes in alternative splicing to MET. Our experiments with
ESRP1 and RBFOX2 splicing factors suggest that epithelial
splicing induced in mesenchymal cells by expression of ESRP1 or
the loss of mesenchymal splicing resulting from depletion of
RBFOX2 are not sufficient to convert gene expression into an
epithelial pattern. However, mesenchymal cells expressing ectopic
ESRP1 or depleted of RBFOX2 exhibited actin organization,
barrier function and migration characteristics shifted significantly
towards an epithelial phenotype, indicative of a partial MET. Our
data along with other reports [58,59] suggest that although
transcriptional control is extremely important to drive EMT,
alternative splicing is required to execute the complex changes
needed for cells to undergo the dramatic phenotypic change from
epithelial to mesenchymal states.
Comparison of EMT-dependent skipped exon events identified
in the current study to ESRP-regulated ones [28,41] revealed that
out of,1500 EMT-dependent events (FDR,0.05), only 116 seem
to be regulated by ESRP1,2 (Figure S11A). Interestingly, ESRP1
expression in clinical samples correlated with the inclusion of an
alternative exon of ENAH but no correlation was observed with
the presence of lymph node metastasis (Figure S11B). PTB and
RBFOX2 may control a number of EMT-driven splicing events,
as evident by a significant overlap between exons associated with
CLIP-Seq tags and exons that undergo splicing changes during
EMT. However, ESRP1, RBFOX2 and PTB together may
regulate only a fraction of all EMT-associated alternative splicing
(Figure 2A, 2C; Figure S11A), so it is likely that other splicing
Figure 7. Expression of ESRP1 changes actin organization and localization of junctional markers in mesenchymal cells towards
epithelial morphology. (A) Immunofluorescence of cells, as indicated, using anti-ZO-1 antibody and Alexa350-phalloidin. Scale bar, 20 mm. Insets
were 56 magnified. (B) Immunofluorescence of cells, as indicated, using anti-p120catenin antibody and Alexa405-phalloidin. Red arrows mark
peripheral actin. Yellow arrows mark stress fibers. Blue arrows mark p120catenin at cell junctions. Scale bar, 5 mm. (C) Bar graph depicting movement
of Texas Red–dextran across confluent monolayers of HMLE cells, as indicated, at 2 hrs and 4 hrs after addition of dextran compared to control cells
expressing pBP (*, P,0.05; n= 6). Error bars represent SD.
doi:10.1371/journal.pgen.1002218.g007
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factors also play important roles in executing the EMT splicing
program. Our RBP motif enrichment analysis suggests involve-
ment of the MBNL family of splicing factors and several hnRNP
proteins, including hnRNPs F/H, L and PTB. Potentially,
alteration of a combination of ESRP1, RBFOX2 and/or other
specific splicing factors could be sufficient to drive many
phenotypic aspects of EMT. In other words, epithelial cells might
potentially bypass the traditional EMT-inducing transcriptional
networks to acquire mesenchymal-like phenotypes, when triggered
by global changes in splicing programs that enable an EMT-like
transformation. This raises the intriguing possibility that instances
where invasion and metastasis occurs without changes in canonical
EMT expression markers may arise from splicing-driven pheno-
typic changes.
EMT in primary breast cancers
Evidence for EMT in clinical carcinomas has been difficult to
obtain, leading to a controversy regarding the role of EMT as a
prerequisite for metastasis. Although EMT and MET have been
observed in the animal model of prostate cancer [60], the presence
of regions of well-differentiated epithelial morphology within some
invasive primary tumors and metastatic lesions appears to conflict
Table 1. Functional consequences of alternative splicing in EMT.
Gene
EMT-relevant gene
functional tendency
Change in the
reading frame dY
RNA and/or protein region
altered by alternative splicing
Inclusion isoform
expressed in
Regulation of actin cytoskeleton
and cell adhesion
WASF1 regulation of actin cytoskeleton alternative first exon (AFE) 20.37 59UTR epithelial
VCL stabilization of E-cadherin
at adherens junctions3
intron retention (RI) 20.22 59UTR epithelial
ABI-2 formation and stability
of cell junctions16
inframe A3SS 20.21 homeo-domain
homologous region
epithelial
PTPRF stabilization of adherens junctions1 inframe inc/del (SE) 20.13 FNIII-like domain 5 (LASE-c)2 epithelial
ILK tumor invasion via
inhibition of E-cadherin15
inframe A3SS 0.34 59UTR mesenchymal
ABL2 regulation of actin remodeling20 alternative first exon (AFE) 0.39 N-terminal mesenchymal
SCRIB tumor suppressor; supports
epithelial cell polarity24
inframe inc/del (SE) 0.39 partially affects PKC
phosphorylation motif
mesenchymal
CTNND1 cell adhesion and signal transduction inframe inc/del (SE) 0.68 N-terminal RhoA binding
stabilization domain
mesenchymal
Induction of EMT
FGFR2 induction of EMT7 MXE 21 IgIII - like domain epithelial
FGFR1 induction of EMT8 MXE 20.54 IgIII - like domain epithelial
STX2 epithelial cell morphogenesis
and activation6
premature Stop 20.46 C-terminal epithelial
VEGFA induction of EMT12 intron retention (RI) 0.4 39UTR mesenchymal
TEAD1 transcriptional activation of
mesenchymal targets4
inframe inc/del (SE) 0.61 internal repeat downstream
of TEA domain5
mesenchymal
Cell motility and invasion
FAT1 enhancement of cell
migration and invasion9
inframe inc/del (SE) 0.38 cytoplasmic domain (FAT1+1210) mesenchymal
PPFIBP1 tumor cell motility and migration11 inframe inc/del (SE) 0.42 phosphorylation motif for Akt1 mesenchymal
NF2 tumor suppressor;
inhibitor of cell migration23
alternative first exon (AFE) 0.37 N-terminal intermolecular
association domain
mesenchymal
TGF-beta pathway
E2F4 mediator of TGF-beta response14 alternative last exon (ALE) 0.24 C-terminal mesenchymal
SMAD2 mediator of EMT induction
via TGF-beta pathway13
alternative first exon (AFE) 0.4 N-terminal mesenchymal
BMP1 promotion of tumor
cell migration21,22
inframe inc/del (SE) 20.13 PKA C-terminal
phosphorylation site
epithelial
Wnt signaling pathway
DKK3 Wnt signaling antagonist19 alternative first exon (AFE) 0.36 59UTR mesenchymal
CSNK1A1 promotes epithelial cell-cell adhesion18 A5SS 0.43 elongated C-terminus mesenchymal
CSNK1G3 Wnt pathway regulation inframe inc/del (SE) 0.55 C-terminal mesenchymal
Column 1, EMT-relevant genes that are alternatively spliced; Column 2, EMT-related function of the corresponding protein; Column 3, the kind of alternative splicing
event; Column 4 indicates the change in the amount of the inclusion isoform (dY=Y(mes)2Y(epi)); Column 5 describes RNA region or a known protein domain
affected; Column 6 indicates whether inclusion isoform is expressed in epithelial or mesenchymal cells.
doi:10.1371/journal.pgen.1002218.t001
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with a role for EMT in metastatic progression [7]. A number of
factors that may account for this discrepancy have been suggested,
including: 1) incomplete EMT may be sufficient for cells to
metastasize; 2) EMT might only occur in a small number of cells
within the tumor mass that would quickly disappear by
intravasating into blood or lymphatic vessels; and, 3) after
colonization, tumor cells revert to an epithelial morphology at
metastatic sites through a reciprocal process of mesenchymal to
epithelial transformation (MET) [13,15]. Thus, clinical samples of
primary tumor and metastatic nodules often do not show evidence
of EMT because the relevant cells display a mesenchymal
phenotype only when they are in transit from the primary tumor
to the site of mestastasis. Moreover, if indeed only a few cells in the
primary tumor undergo EMT prior to migration, RNA from these
cells would be diluted by RNA from the luminal parts of the tumor
in qRT-PCR analyses. FNA samples seem to be an attractive
alternative to assess EMT. FNA of some IDCs, where many cells
are loosely attached to the tumor mass, collect motile cells that
may already be ‘in transit’ from the primary tumor to secondary
sites, some of which might presumably have undergone EMT.
In our analysis of EMT-associated splicing changes in IDCs
from breast cancer patients collected by FNA, we identified two
groups of IDCs. In one group, inclusion of a set of epithelial
splicing events was observed; while in a second group inclusion of
mesenchymal splicing events was detected, suggesting a post-EMT
phenotype. These data indicate that in some of the IDCs, tumor
cells underwent EMT, consistent with the idea that EMT is
associated with, and can contribute to cancer progression. We
hypothesize that IDCs where mesenchymal splicing events were
identified are more likely to metastasize than tumors exhibiting the
epithelial splicing pattern, since recent studies suggest that
expression of EMT program is associated with poor clinical
outcome in some tumor types [61,62].
EMT–associated alternative splicing events as potential
prognostic and diagnostic markers for breast cancer
metastasis
Splicing aberrations have been associated with several diseases,
including cancer, where altered splicing can lead to production of
protein isoforms with oncogenic properties [63]. A large-scale
analysis of alternative splicing in ductal breast tumors of 600
cancer-associated genes identified 41 breast cancer-specific
markers that discriminate between normal breast tissue and ductal
breast tumors [64]. A number of shared splicing events have been
recently demonstrated in a panel of breast and ovarian cancers
using a high throughput RT-PCR approach [65]. Exon array
analysis was recently used to identify subtype-specific alternative
splicing events in a panel of breast cancer cell lines [26].
Therefore, it appears likely that alternative splicing analysis will
dramatically increase the pool of potential biomarkers for cancer
diagnostics.
Since EMT is considered an early event in the metastatic
process, splicing changes associated with EMT in particular have
the potential to become useful prognostic and diagnostic markers
for breast cancer metastasis. Analysis of the EMT-driven splicing
events in the NCI-60 panel of breast cancer cell lines [39]
demonstrated that many of the EMT-associated alternative
isoforms are expressed. Furthermore, luminal and basal B cell
lines could be distinguished based solely on their splicing patterns,
suggesting that EMT-associated alternative splicing events may
serve as useful markers for classification of breast cancer cell lines
and potentially of human cancers. Moreover, we identified splicing
events that might be considered novel markers of EMT in vivo.
Alternative splicing of ENAH, MLPH, ARHGEF11, MBNL1,
FLNB and SLC37A2 transcripts have been confirmed in a
number of IDC FNAs, suggesting that our EMT-associated
splicing signature may have a prognostic or diagnostic potential.
However, a mesenchymal splicing pattern did not correlate with
the presence of lymph node metastasis. This finding is not
surprising since FNA samples were obtained from recently
diagnosed cancer patients and no follow up information is
available regarding a possible relapse or metastatic status of the
tumor. Therefore, we cannot draw a meaningful conclusion about
the overall relevance of the splicing pattern in relation to outcome
or presence of lymph node metastasis. Although lymph node status
is considered an independent prognostic factor for relative survival
of breast cancer patients (National Cancer Institute website), the
presence of regional lymph node metastases does not always
correlate with subsequent distant spread possibly because the
mechanisms of hematogenous spread are different from those for
lymphatic spread [66]. Within the clinical groups created using
tumor size and lymph node involvement, there is a spectrum of
disease behavior. Even patients with stage I lymph node negative
breast cancer have 15–25% chance of developing distant
metastasis, so breast cancers of early stage must be composed of
mixed phenotypes that cannot be stratified using standard
approaches such as lymph node status, or tumor size [67]. Thus,
an EMT splicing signature may help to stratify early stage breast
cancers, however additional studies will be required to determine
the prognostic potential of EMT-associated splicing events that we
have validated in FNA samples.
A growing body of evidence suggests that EMT is responsible
for acquisition of therapeutic resistance by cancer cells [13].
EMT has been implicated in the generation of cancer cells with
stem-like characteristics that have a high tumor-initiating
potential [68]. Cancer stem cells have been found enriched in
residual breast tumors after chemo- or endocrine therapy [68], in
colorectal cancer cells after oxaliplatin treatment [69], or in
ovarian carcinoma cells after exposure to paclitaxel [70]. Clinical
evidence suggests that expression of mesenchymal markers is
increased in breast tumors after letrozole or docetaxcel treatment
[68]. This indicates that EMT-associated alternative splicing
events that we confirmed in FNA samples from patients with
IDCs may potentially become predictive biomarkers that can be
used for patient selection and/or provide information early
during therapy. Further studies specifically designed to identify
alternative splicing markers that reflect distinct breast cancer
biology in relation to clinical outcomes and prognoses show
promise to improving our understanding of EMT and breast
cancer at the molecular level.
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Cell culture
Immortalized human mammary epithelial cells (HMLEs)
expressing either the empty pBabe puro vector (pBP), pBP-Twist
or pWZL-Twist-ER were obtained from Robert Weinberg’s
laboratory at the Whitehead Institute for Biomedical Research
(Cambridge, MA) and cultured as described previously [71]. 4-
hydroxy tamoxifen (4-OHT) treatment was performed as
described previously [29]. Other plasmids used in this study,
procedures used to produce virus, the procedure for the infection
of target cells, and the derivation of different cell lines are provided
as Text S1.
Antibodies, Western blotting, and immunofluorescence
Cells were lysed in the presence of 50 mM Tris, pH 8.0,
150 mM NaCl, 0.1% SDS, 0.5% Na-Deoxycholate and 1.0% NP-
40 on ice. Twenty micrograms of total protein from each sample
were resolved on an 8%–10% SDS-PAGE Gel with Laemmli
Running Buffer and transferred to PVDF membranes. The blots
were then probed with various antibodies, such as anti-Mena, and
anti-Mena-11a, anti-E-cadherin (BD Transduction), anti-Fibro-
nectin (BD Transduction), anti-vimentin V9 (NeoMarkers), or
anti-N-cadherin (BD Transduction). Detailed immunofluorescence
methods are provided in the Text S1.
cDNA library preparation for Illumina sequencing
Total RNA was extracted from untreated HMLE/Twist-ER
cells (epithelial sample) and after prolonged 4-OHT treatment
(mesenchymal sample) using RNeasy Plus Mini kit (Qiagen). Poly-
T capture beads were used to isolate mRNA from 10 mg of total
RNA. mRNA was fragmented and used for a first-strand cDNA
synthesis by random hexamer-primed reverse transcription and
subsequent second-strand cDNA synthesis. Sequencing adaptors
were ligated using the Illumina Genomic DNA sample prep kit.
Fragments 200 bp long were isolated by gel electrophoresis,
amplified by 16 cycles of PCR, and sequenced on the Illumina
Genome Analyser, as described previously [20].
Computational analyses of RNA–Seq, exon array data,
motif analysis, and clustering
Computational and statistical methods are described in the Text
S1. Briefly, for analysis of RNA-seq data, reads were mapped to
the union of the genome and a database of junctional sequences
derived from AceView/Acembly annotation. Expression analysis
was based on reads that were mapped to constitutive exons among
annotated RefGene transcripts of each gene. Splicing analysis was
based on read density supporting either isoforms of an alternative
splicing event from a database of alternative isoform events. For
more details see the Text S1. Alignment and raw sequencing reads
were deposited in Gene Expression Omnibus with accession
number GSE30290.
Reverse transcriptase PCR analysis
Total RNA for validation of splicing events in HMLE/Twist-
ER cells was extracted using RNeasy Plus Mini kit (Qiagen) and
reverse transcribed with Superscript II (Invitrogen). The resulting
cDNA was used for 25 cycles of PCR with primers listed in the
Text S1. Then samples were subjected to 10%TBE gel
electrophoresis (Bio-Rad), stained with SYBR Safe DNA Gel
Stain (Invitrogen), scanned (Typhoon, GE Healthcare) and
quantified (ImageQuant 5.2). Total RNA from FNA samples
was extracted using RNeasy Plus Micro kit (Qiagen). The resulting
cDNAs were used for qPCR analysis using iQ Syber-Green
Supermix (BioRad) in triplicates. qPCR and data collection were
performed on iCycler (BioRad). Primer sequences used to amplify
cDNAs and the detailed description of quantification analysis are
listed in the Text S1.
Human tissue selection and FNA biopsy procedure
Lumpectomy and mastectomy specimens that arrive to grossing
rooms at AECOM hospitals Montefiore andWeiler for pathological
examination were used for tissue collection. The specimens were
sectioned as usual at 0.5 or 1.0 cm intervals to locate and visualize
the lesion of interest. Four to 5 FNA aspiration biopsies (passes) were
performed on grossly visible lesions using 25 gauge needles. When
an FNA needle is inserted into a malignant tumor it preferentially
collects loose tumor cells, as can be noted on FNA obtained smears
in Figure 5 and Figure S5. A small number of other cell types may
also be present, most commonly inflammatory cells and macro-
phages. The aspirated material was collected in the cryo-vials, and
to assess the adequacy of the sample, a small portion of the aspirated
material was taken out of the vial, smeared on a glass slide, air-dried
and stained by standard Diff-Quick protocol. The adequacy of the
sample was determined by cytopathologic microscopic examination
of the smears. Only samples composed of 95% of either benign or
malignant epithelial cells were used in the study. Standard
cytopathologic criteria such as cell size, nuclear/cytoplasmic ratio,
nuclear contours, cell crowding and cohesiveness of the cells were
the major criteria for classification into benign or malignant
category. Samples containing a mixture of malignant and benign
cells, necrotic cell debris, or more than 5% of inflammatory or
stromal cells as determined by cytopathologic microscopic exam-
ination were discarded. FNA biopsy samples were immediately snap
frozen in liquid nitrogen and stored frozen for RNA isolation
followed by a qPCR analysis. Specimens were collected without
patient identifiers following protocols approved by the Montefiore
Medical Center Institutional Review Board.
Cell migration assays
Matrigel overlay assay was performed as previously described
[42]. 105 cells were mixed with 3.5 mg/ml matrigel and
polymerized in a drop on top of the matrigel-covered coverslip.
Images of migrating cells at 0, 8 hr, 19 hrs, 24 hrs time points
were obtained on a Nikon Eclipse TE200 using a 106 DIC
objective. Cell migration assay was performed as previously
described [43,72]. Cells were incubated with CMFDA (Invitrogen)
for 10 minutes and seeded overnight. Labeled and unlabeled cells
were seeded at a 1:20 ratio. In 24 hrs, cells were placed on an
environment-controlled Nikon TE2000 microscope (Nikon Instru-
ments; Melville, NY) and were imaged every 10-minutes for
12 hrs. Image sequences were analyzed with Bitplane Imaris
software (Zurich, Switzerland) using the built-in ‘Spots’ function.
12-hour tracks were generated using the ‘Brownian Motion’
algorithm.
Permeability assay
HMLE/pBP-EGFP, HMLE/pBP-Twist-EGFP and HMLE/
pBP-Twist/ESRP1-EGFP cells were seeded at confluence on
polycarbonate transwell membrane inserts (3.0 mm pore size;
Falcon 353492) and cultured for 3 d. 70 kD of Texas red–dextran
(Invitrogen) was added to the top chamber at 2 mg/ml, and its
movement into the bottom chamber was monitored over 4 hrs by
spectrophotometer.
Supporting Information
Figure S1 RNA–Seq analysis and validation. (A) The table and
pie charts indicate total read numbers obtained for each sample
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and efficiency of their mapping to the human genome using
AceView annotation. (B) Western blot analysis of cell lysates from
HMLE/Twist-ER, MCF7 and T47D probed with antibodies as
indicated. (C) Read density in exonic and intronic regions is
plotted as a function of RPKM in epithelial and mesenchymal
samples. (D) Comparison of DY=Y(Mesenchymal)2Y(Epithelial)
value defined by RNA-seq analysis to the DY determined
experimentaly by semi-quantitative RT-PCR.
(TIF)
Figure S2 EMT is accompanied by a massive change in gene
expression. (A) Scatter plot of gene expression during EMT.
RPKM values were plotted for epithelial (x axis) and mesenchymal
(y axis) samples. Genes upregulated in the mesenchymal sample
are marked by red and purple dots, as indicated. Genes
upregulated in the epithelial sample are marked by light and dark
green dots, as indicated. Genes whose expression did not change
are marked in blue. (B) and (C) Gene ontology enrichment analysis
of genes downregulated (B) and upregulated in EMT. Gene
ontology ‘biological process’, GO_BP_FAT, annotation is depict-
ed in red on the y axis. KEGG Pathway analysis (http://www.
genome.jp/kegg/) annotation is depicted in blue on y axis.
Benjamini FDR (2log10) is indicated on the x axis. Vertical dotted
line marks Benjamini FDR=0.05.
(TIF)
Figure S3 Regulation of gene expression is independent from
regulation of alternative splicing during Twist-induced EMT.
Cumulative Density Function (CDF) plot of the distribution of
gene expression changes among genes that are alternative spliced
(fg (genes with SE events FDR,0.05, |dPsi|.0.1), red line), and
not alternatively spliced during EMT (bg (genes in powerset but
not in fg), blue dotted line). Kolmogorov-Smirnov (KS) test p-
value = 0.69.
(TIF)
Figure S4 Coherence between NCI-60 array data and EMT
RNA-Seq dataset increases for highly changed EMT-associated
SE events. A bar graph demonstrating the fraction of coherent
events between EMT RNA-seq and a panel of NCI-60 breast
cancer cell lines [41] as a function of RNA-seq |DY| cut-offs. The
number of events called significant at the corresponding RNA-seq
|DY| cut-offs and exon array FDR,0.25 [41] is depicted above
each column.
(TIF)
Figure S5 FNA samples contain negligible amounts of stromal
or inflammatory cells. (A) Cellular composition of 15 IDC FNA
samples randomly chosen from the 40 FNA samples analyzed in
this study. Relative amounts of ductal carcinoma cells (tumor
cells), inflammatory cells, and adipocytes and macrophages
(stromal cells) are depicted for each sample. (B) Average cellular
composition of 15 IDC FNA samples randomly chosen from the
40 FNA samples analyzed in this study. Average relative amounts
of ductal carcinoma cells (Tumor cells), inflammatory cells and
adipocytes and macrophages (stromal cells) are depicted. Error
bars represent SEM. (C) Two representative images of IDC FNA
spread. Red error marks fatty droplet. Black error marks
inflammatory cell.
(TIF)
Figure S6 Epithelial and mesenchymal inclusion patterns in
IDC FNA samples are negatively correlated. (A) Heatmap of six
exon inclusion events in FNA samples. The exon inclusion levels
were rescaled into [21,1] and are depicted as shades of red and
green. Gray boxes represent data not available (NA). Sample ID is
shown to the right. (B) Pvclust clustering tree of six exon inclusion
events in (A). AU p-value (confidence) of each subtree is indicated
at each branchpoint. The Pearson distance is shown in a ruler on
the left. All AU p-values.0.9, and the main epithelial subtree and
mesenchymal subtree achieve AU p-value.0.99 indicating the
reliability of the clustering tree.
(TIF)
Figure S7 Comparison of the migration behavior of HMLE/
pBP, HMLE/pBP-Twist and HMLE/pBP-Twist/ESRP1 cells.
Cells were plated in a matrigel drop on top of a thin matrigel layer
and allowed to migrate out of the drop for 24 hrs. Migration was
followed using 106DIC imaging at time intervals after the start of
the experiment, as indicated. Red line marks the boundary of the
initial matrigel drop. Scale bar, 100 mm.
(TIF)
Figure S8 Monolayer migration assay analysis. (A) Phase contrast
images of cells, as indicated, plated in a monolayer for the cell tracking
experiment in Figure 6. (B) Box plots depict migration parameters
inferred from live-cell imaging experiment of cells in Figure 6 and
analyzed by the Imaris software. Edges of the boxes indicate 25th and
75th percentile and the whiskers 5th and 95th percentile. The line in the
box indicates the median of the distribution. n=138 cells for HMLE/
pBP; n=125 cells for HMLE/pBP-Twist; n=113 cells for HMLE/
pBP-Twist/ESRP1-EGFP. ***=p,0.001.
(TIF)
Figure S9 Immunofluorescence analysis of cell-cell junctions in
HMLE cells. (A) and (B) Immunofluorescence of cells, as indicated,
using anti-alpha-catenin (A) and p120 catenin (B) antibodies and
Alexa350-phalloidin. Scale bar, 20 mm. Insets were 56magnified.
(TIF)
Figure S10 Depletion of RBFOX2 confers epithelial-like prop-
erties to mesenchymal cells. (A) qPCR analysis of RBFOX2 levels in
HMLE/pBP-Twist cells expressing scrambled shRNA or RBFOX2
shRNA using two different primer pairs. (B) RT-PCR analysis of
alternative exon inclusion in FAT and PLOD2 in HMLE/pBP-
Twist cells expressing scrambled shRNA or RBFOX2 shRNA, as
indicated. E marks excluded isoform, I marks included isoform. (C)
Western blot analysis of EMT markers and RBFOX2 expression in
scrambled or RBFOX2 shRNA treated cells, as indicated. (D)
Immunofluorescence analysis of cell junctions using anti-ZO-1,
anti-p120catenin, anti-alpha-catenin antibodies and Alexa-350
phalloidin, as indicated. Scale bar 15 mm. Insets were 56magnified.
(E) Comparison of the migration behavior of HMLE/pBP-Twist
cells expressing scrambled or RBFOX2 shRNA. For a detailed
description see the legend to Figure S4.
(TIF)
Figure S11 ESRP1,2 regulate a subset of EMT-dependent
skipped exon events. (A) Venn diagram showing the overlap of
skipped exon events reported in Warzecha et al 2009, 2010
[31,43], and identified from our EMT RNA-seq dataset
(FDR,0.05). 1391 events are unique to EMT RNA-seq dataset,
780 events are unique to the union of Warzecha et al 2009, 2010
[31,43] datasets, 116 are common to both datasets. The numbers
beneath the circles denote the number of events reported in the
current study and in Warzecha et al 2009, 2010. (B) Heatmap of
the ESRP expression levels and exon inclusion level of ENAH
alternative exon. The expression values and exon inclusion levels
are rescaled into [21,1] and depicted as shades of red and green.
Sample rows were sorted by ESRP1 expression. Sample ID is
shown to the right of the heatplot. Lymphnode metastasis for
corresponding samples is shown as red (LN positive) and black (LN
negative) circles.
(TIF)
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Table S1 Skipped and Mutually Exclusive alternative splicing
events with FDR,0.05 and |DY|$0.03. Column 1 marks the
type of event: SE-skipped exon, MXE- mutually exclusive exon.
Column 2 - Gene symbol. Column 3 – Ensembl Gene ID. Column
4 - the chromosome number where the gene is located. Column 5
- DNA strand on which the gene is encoded. Column 6 - exon
coordinates of the flanking and alternative exons: for SE events -
,upstream flanking exon., ,alternative exon., ,downstream
flanking exon./,upstream flanking exon., ,downstream
flanking exon.; for MXE events - ,upstream flanking exon.,
,alternative exon 1.,,downstream flanking exon./,upstream
flanking exon., alternative exon 2., ,downstream flanking
exon.. Column 7 - the Y of the alternative event in the epithelial
(pre-EMT) sample. Column 8 - the Y of the alternative event in
the mesenchymal (post-EMT) sample. Column 9 - DY=Y(me-
s)2Y(epi). Column 10 – FDR.
(XLS)
Table S2 The 5-mers enriched in foreground set over
background set of unchanged exons in 250 nt flanking intronic
sequences of skipped exons and upstream and downstream exons
(FDR,0.05, DY.0.1). Annotation details: [] are the two flanking
exons, ,. is the skipped exon: [inUFSeq] I5 ----- I3 , inMFSeq
. I5 ------ I3 [inDFSeq]. Column 1 (Exon) indicates a reference
exon of the intronic element analyzed. Column 2 (Element)
indicates intronic element analyzed: I5- 59 sequence of the intron,
I3- 39 sequence of the intron. Column 3 (p-value) - the
hypergeometric p-value of the 5mer frequency in foreground over
that of the background. Column 4 (FDR) - B-H multiple
comparison FDR of the p-value. Column 5 (background rate) -
the density of the 5mer in the background (set of unchanged SE
events). Column 6 (expected frequency) - the expected count of the
5mer in the foreground given the background rate. Column 7
(foreground rate) - the density of the 5mer in the foreground (set of
changed SE events). Column 8 (foreground frequency) - the count
of the 5mer in the foreground. Column 8 (word) demonstrates the
sequence of the 5mer.
(XLS)
Table S3 The 5-mers enriched in foreground set over
background set of unchanged exons in 250 nt flanking intronic
sequences of skipped exons and upstream and downstream exons
(FDR,0.05, DY,20.1). Annotation details: [] are the two
flanking exons, ,. is the skipped exon: [inUFSeq] I5 ----- I3 ,
inMFSeq . I5 ------ I3 [inDFSeq]. Column 1 (Exon) indicates a
reference exon of the intronic element analyzed. Column 2
(Element) indicates intronic element analyzed: I5- 59 sequence of
the intron, I3- 39 sequence of the intron. Column 3 (p-value) - the
hypergeometric p-value of the 5mer frequency in foreground over
that of the background. Column 4 (FDR) - B-H multiple
comparison FDR of the p-value. Column 5 (background rate) -
the density of the 5mer in the background (set of unchanged SE
events). Column 6 (expected frequency) - the expected count of the
5mer in the foreground given the background rate. Column 7
(foreground rate) - the density of the 5mer in the foreground (set of
changed SE events). Column 8 (foreground frequency) - the count
of the 5mer in the foreground. Column 8 (word) demonstrates the
sequence of the 5mer.
(XLS)
Table S4 Expression levels of RNA-binding proteins. Column1 -
The Gene symbol. Column 2 - the RPKM value of the gene in the
epithelial (pre-EMT) sample. Column 3 - the RPKM value of the
gene in mesenchymal sample. Column 4 (Ratio) - the ratio of
RPKM values (Mes/Epi).
(XLS)
Table S5 Characteristics of the invasive ductal carcinoma (IDC)
samples used for the FNA qPCR analysis. Column 1 – samples
number; Column 2- tumor size (cm); Column 3 – greatest
diameter of the tumor (cm); Column 4 – tumor grade according to
the modified Bloom-Richardson scale (1–9). Differentiation status:
M- moderate, P – poor, W-well; Columns 5–8 – growth hormone
receptor and lymph node status: ER-estrogen receptor, PR-
progesterone receptor, Her2 – EGF receptor, LN – lymph node.
(XLS)
Text S1 Supplementary Experimental Procedures.
(DOC)
Video S1 HMLE/pBP cells migrate efficiently in a monolayer.
HMLE/pBP cells were labeled with a cellular dye CMFDA and
seeded in a confluent monolayer mixed 1:20 with unlabelled cells.
Cells were imaged for 12 hours with 10 min intervals. Cell tracks
were generated using semi-automated cell tracking and represent
single cell tracks over 12 hours. Centroids of fluorescent cells are
marked by grey circles.
(MOV)
Video S2 Monolayer migration of HMLE/pBP- Twist cells is
cell-contact inhibited. HMLE/pBP-Twist cells were labeled with a
cellular dye CMFDA and seeded in a confluent monolayer mixed
1:20 with unlabelled cells. Cells were imaged for 12 hours with
10 min intervals. Cell tracks were generated using semi-automated
cell tracking and represent single cell tracks over 12 hours.
Centroids of fluorescent cells are marked by grey circles.
(MOV)
Video S3 HMLE/pBP- Twist/ESRP1-EGFP cells demonstrate
significant locomotion. HMLE/pBP-Twist/ESRP1-EGFP cells
were labeled with a cellular dye CMFDA and seeded in a
confluent monolayer mixed 1:20 with unlabelled cells. Cells were
imaged for 12 hours with 10 min intervals. Cell tracks were
generated using semi-automated cell tracking and represent single
cell tracks over 12 hours. Centroids of fluorescent cells are marked
by grey circles.
(MOV)
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